235 related articles for article (PubMed ID: 17107349)
1. t(8;21) acute myeloid leukaemia cells are dependent on vascular endothelial growth factor (VEGF)/VEGF receptor type2 pathway and phosphorylation of Akt.
Imai N; Shikami M; Miwa H; Suganuma K; Hiramatsu A; Watarai M; Satoh A; Itoh M; Imamura A; Mihara H; Nitta M
Br J Haematol; 2006 Dec; 135(5):673-82. PubMed ID: 17107349
[TBL] [Abstract][Full Text] [Related]
2. Growth inhibition of AML cells with specific chromosome abnormalities by monoclonal antibodies to receptors for vascular endothelial growth factor.
Imai N; Miwa H; Shikami M; Suganuma K; Gotoh M; Hiramatsu A; Wakabayashi M; Watarai M; Hanamura I; Imamura A; Mihara H; Shitara K; Shibuya M; Nitta M
Leuk Res; 2009 Dec; 33(12):1650-7. PubMed ID: 19342098
[TBL] [Abstract][Full Text] [Related]
3. Vascular endothelial growth factor receptor-1 and receptor-2 initiate a phosphatidylinositide 3-kinase-dependent clonogenic response in acute myeloid leukemia cells.
List AF; Glinsmann-Gibson B; Stadheim C; Meuillet EJ; Bellamy W; Powis G
Exp Hematol; 2004 Jun; 32(6):526-35. PubMed ID: 15183893
[TBL] [Abstract][Full Text] [Related]
4. AEE788 is a vascular endothelial growth factor receptor tyrosine kinase inhibitor with antiproliferative and proapoptotic effects in acute myeloid leukemia.
Barbarroja N; Torres LA; Rodriguez-Ariza A; Valverde-Estepa A; Lopez-Sanchez LM; Ruiz-Limon P; Perez-Sanchez C; Carretero RM; Velasco F; López-Pedrera C
Exp Hematol; 2010 Aug; 38(8):641-52. PubMed ID: 20380868
[TBL] [Abstract][Full Text] [Related]
5. Disease-specific expression of VEGF and its receptors in AML cells: possible autocrine pathway of VEGF/type1 receptor of VEGF in t(15;17) AML and VEGF/type2 receptor of VEGF in t(8;21) AML.
Hiramatsu A; Miwa H; Shikami M; Ikai T; Tajima E; Yamamoto H; Imai N; Hattori A; Kyo T; Watarai M; Miura K; Satoh A; Itoh M; Imamura A; Mihara H; Katoh Y; Nitta M
Leuk Lymphoma; 2006 Jan; 47(1):89-95. PubMed ID: 16465716
[TBL] [Abstract][Full Text] [Related]
6. Vascular endothelial growth factor acts in an autocrine manner in rhabdomyosarcoma cell lines and can be inhibited with all-trans-retinoic acid.
Gee MF; Tsuchida R; Eichler-Jonsson C; Das B; Baruchel S; Malkin D
Oncogene; 2005 Dec; 24(54):8025-37. PubMed ID: 16116481
[TBL] [Abstract][Full Text] [Related]
7. Tissue factor pathway inhibitor-2 is upregulated by vascular endothelial growth factor and suppresses growth factor-induced proliferation of endothelial cells.
Xu Z; Maiti D; Kisiel W; Duh EJ
Arterioscler Thromb Vasc Biol; 2006 Dec; 26(12):2819-25. PubMed ID: 17023682
[TBL] [Abstract][Full Text] [Related]
8. Expression and significance of vascular endothelial growth factor receptor 2 in bladder cancer.
Xia G; Kumar SR; Hawes D; Cai J; Hassanieh L; Groshen S; Zhu S; Masood R; Quinn DI; Broek D; Stein JP; Gill PS
J Urol; 2006 Apr; 175(4):1245-52. PubMed ID: 16515971
[TBL] [Abstract][Full Text] [Related]
9. [Activation of signal transducers and activators of transcription induced by vascular endothelial growth factor in CD34+ hematopoietic progenitor cells in vitro].
Ye F; Ye DF; Xie X; Chen HZ; Lü WG
Zhongguo Yi Xue Ke Xue Yuan Xue Bao; 2004 Feb; 26(1):12-7. PubMed ID: 15052767
[TBL] [Abstract][Full Text] [Related]
10. Additive effect of PTK787/ZK 222584, a potent inhibitor of VEGFR phosphorylation, with Idarubicin in the treatment of acute myeloid leukemia.
Barbarroja N; Torres LA; Luque MJ; Carretero RM; Valverde-Estepa A; Lopez-Sanchez LM; Rodriguez-Ariza A; Velasco F; Torres A; López-Pedrera C
Exp Hematol; 2009 Jun; 37(6):679-91. PubMed ID: 19463770
[TBL] [Abstract][Full Text] [Related]
11. Non-redundant roles of the Gab1 and Gab2 scaffolding adapters in VEGF-mediated signalling, migration, and survival of endothelial cells.
Caron C; Spring K; Laramée M; Chabot C; Cloutier M; Gu H; Royal I
Cell Signal; 2009 Jun; 21(6):943-53. PubMed ID: 19233262
[TBL] [Abstract][Full Text] [Related]
12. Effects of SU5416, a small molecule tyrosine kinase receptor inhibitor, on FLT3 expression and phosphorylation in patients with refractory acute myeloid leukemia.
O'Farrell AM; Yuen HA; Smolich B; Hannah AL; Louie SG; Hong W; Stopeck AT; Silverman LR; Lancet JE; Karp JE; Albitar M; Cherrington JM; Giles FJ
Leuk Res; 2004 Jul; 28(7):679-89. PubMed ID: 15158089
[TBL] [Abstract][Full Text] [Related]
13. Inhibition of tumor cell growth, invasion, and metastasis by EXEL-2880 (XL880, GSK1363089), a novel inhibitor of HGF and VEGF receptor tyrosine kinases.
Qian F; Engst S; Yamaguchi K; Yu P; Won KA; Mock L; Lou T; Tan J; Li C; Tam D; Lougheed J; Yakes FM; Bentzien F; Xu W; Zaks T; Wooster R; Greshock J; Joly AH
Cancer Res; 2009 Oct; 69(20):8009-16. PubMed ID: 19808973
[TBL] [Abstract][Full Text] [Related]
14. (-)-Epigallocatechin gallate suppresses the growth of human hepatocellular carcinoma cells by inhibiting activation of the vascular endothelial growth factor-vascular endothelial growth factor receptor axis.
Shirakami Y; Shimizu M; Adachi S; Sakai H; Nakagawa T; Yasuda Y; Tsurumi H; Hara Y; Moriwaki H
Cancer Sci; 2009 Oct; 100(10):1957-62. PubMed ID: 19558547
[TBL] [Abstract][Full Text] [Related]
15. Targeting of mTOR is associated with decreased growth and decreased VEGF expression in acute myeloid leukaemia cells.
Böhm A; Aichberger KJ; Mayerhofer M; Herrmann H; Florian S; Krauth MT; Derdak S; Samorapoompichit P; Sonneck K; Vales A; Gleixner KV; Pickl WF; Sperr WR; Valent P
Eur J Clin Invest; 2009 May; 39(5):395-405. PubMed ID: 19320940
[TBL] [Abstract][Full Text] [Related]
16. Interactions between sphingosine-1-phosphate and vascular endothelial growth factor signalling in ML-1 follicular thyroid carcinoma cells.
Balthasar S; Bergelin N; Löf C; Vainio M; Andersson S; Törnquist K
Endocr Relat Cancer; 2008 Jun; 15(2):521-34. PubMed ID: 18509004
[TBL] [Abstract][Full Text] [Related]
17. AMG 706, an oral, multikinase inhibitor that selectively targets vascular endothelial growth factor, platelet-derived growth factor, and kit receptors, potently inhibits angiogenesis and induces regression in tumor xenografts.
Polverino A; Coxon A; Starnes C; Diaz Z; DeMelfi T; Wang L; Bready J; Estrada J; Cattley R; Kaufman S; Chen D; Gan Y; Kumar G; Meyer J; Neervannan S; Alva G; Talvenheimo J; Montestruque S; Tasker A; Patel V; Radinsky R; Kendall R
Cancer Res; 2006 Sep; 66(17):8715-21. PubMed ID: 16951187
[TBL] [Abstract][Full Text] [Related]
18. Colocalization of the VEGF-R2 and the common IL-3/GM-CSF receptor beta chain to lipid rafts leads to enhanced p38 activation.
Saulle E; Riccioni R; Coppola S; Parolini I; Diverio D; Riti V; Mariani G; Laufer S; Sargiacomo M; Testa U
Br J Haematol; 2009 May; 145(3):399-411. PubMed ID: 19245429
[TBL] [Abstract][Full Text] [Related]
19. FHL-2 suppresses VEGF-induced phosphatidylinositol 3-kinase/Akt activation via interaction with sphingosine kinase-1.
Hayashi H; Nakagami H; Takami Y; Koriyama H; Mori M; Tamai K; Sun J; Nagao K; Morishita R; Kaneda Y
Arterioscler Thromb Vasc Biol; 2009 Jun; 29(6):909-14. PubMed ID: 19325137
[TBL] [Abstract][Full Text] [Related]
20. Programmed cell death-4 tumor suppressor protein contributes to retinoic acid-induced terminal granulocytic differentiation of human myeloid leukemia cells.
Ozpolat B; Akar U; Steiner M; Zorrilla-Calancha I; Tirado-Gomez M; Colburn N; Danilenko M; Kornblau S; Berestein GL
Mol Cancer Res; 2007 Jan; 5(1):95-108. PubMed ID: 17259349
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
